Thousands of New Zealanders with lymphoma, breast, ovarian and blood cancers will have more treatment options available to them in the New Year.
Patients taking lamotrigine who have concerns about the change can talk with their doctor about remaining on their current brand as PHARMAC has widened the criteria for lamotrigine exceptional circumstances.
The meningococcal ACWY vaccine will be available free from next month for young people in close living situations.
New Zealanders with chronic lymphocytic leukaemia will have another medicine option available to help them live longer from 1 December 2019.
PHARMAC is widening funded access to Mirena, as well as listing a new long-acting reversible contraceptive option, Jaydess, which will benefit around 21,000 New Zealand women.
420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier.
The agreement with Roche Products (New Zealand) includes funding three new treatments, as well as widened access to one currently funded treatment.
From today there will be one funded brand of lamotrigine - a medicine used to treat epilepsy and some mental health conditions, including bipolar disorder.
There are several suppliers that make lamotrigine – each with their own brand. PHARMAC has decided to change from funding three different brands (Lamictal, Arrow-Lamotrigine and Logem) to funding the Logem brand only.
PHARMAC has reached a deal with pharmaceutical companies for three new medicines to treat ovarian cancer, breast cancer and leukaemia.
PHARMAC has distributed over 1.26 million doses of the influenza vaccine this winter.
The 2019 Tapuhi Kaitiaki Awards, jointly awarded by PHARMAC and Te Rūnanga o Aotearoa/New Zealand Nurses Organisation (NZNO) and presented in August will both celebrate and support Māori nurses to continue in their studies and improve their clinical practice. Nominations/applications are now open.
Over 1500 New Zealanders have started a new hepatitis C treatment in the last three months that could dramatically change their lives.
PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will make a major difference to their lives, PHARMAC Director of Operations Lisa Williams says.
An overhaul of PHARMAC’s decision-making process will give better insight into what medicines are - and are not - being actively considered for funding, Chief Executive, Sarah Fitt says.
Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February 2019, after PHARMAC funds a new treatment.
Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has reached with Novartis, which makes more funded medicines available for a wide range of health conditions.
PHARMAC is celebrating the formation of New Zealand’s first Pacific Pharmacists’ Association. PHARMAC Chief Executive, Sarah Fitt, says PHARMAC is proud to support Pacific pharmacists working...
PHARMAC and Te Pōari o Te Rūnanga o Āotearoa and their Tiriti partner Tōpūtanga Tapuhi Kaitiaki o Āotearoa (NZNO) are pleased to announce the inaugural recipients of the Tapuhi Katiaki Awards.
If you get a cold or flu this winter, taking antibiotics won’t fix it.
PHARMAC is progressing work aimed at improving funded access to medicines for rare disorders.
PHARMAC is pleased to provide another treatment option for patients with severe osteoporosis following the funding of denosumab, brand name Prolia, from 1 July 2018.